Innovative therapeutics

Investors

NASDAQBMRN
FormDescriptionDateFormat
ARSAn annual report to security holders.Apr 6, 2010Open An annual report to security holders. in HTML.Open An annual report to security holders. in DOC file.Open An annual report to security holders. in PDF file.Open An annual report to security holders. in XLS file.
10-K/AAmendment to a previously filed 10-KMar 25, 2010Open Amendment to a previously filed 10-K in HTML.Open Amendment to a previously filed 10-K in DOC file.Open Amendment to a previously filed 10-K in PDF file.Open Amendment to a previously filed 10-K in XLS file.
10-KAnnual report which provides a comprehensive overview of the company for the past yearFeb 26, 2010Open Annual report which provides a comprehensive overview of the company for the past year in HTML.Open Annual report which provides a comprehensive overview of the company for the past year in DOC file.Open Annual report which provides a comprehensive overview of the company for the past year in PDF file.Open Annual report which provides a comprehensive overview of the company for the past year in XLS file.

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq®
Brineura®
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information